Baird Reiterates Bullish View on Sarepta (SRPT) Following Eteplirsen NDA Acceptance
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $47 price target on Sarepta Therapeutic (NASDAQ: SRPT) after eteplirsen NDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
